This meta-analysis systematically evaluated the impact of three major classes of novel glucose-lowering drugs—SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors—on the risk of seven clinically relevant respiratory diseases. The gene discussed is DPP4; the disease is respiratory system disorder.